[vc_row][vc_column][vc_column_text css=”.vc_custom_1652965552718{margin-bottom: 0px !important;}”]In 2020, we published an article covering 91 drug patents expiring between 2020-2022. 2022 is already here, and if you are working in the pharma domain, working on the development of generics, you would want to know what drug patents are expiring in the coming years so you can plan accordingly.
With the explosive growth in the generic drug market, generic companies (like yours) are in a battle to claim a share of the soon-to-be-expired drugs as quickly as possible. You would want to know as much as possible, and keeping that very thought in mind, we collated a list of 51 drugs that are going off-patent in 2023. We also included other information like yearly sales, dosage information, ingredients, and the diseases they cure. This could help you easily choose the most profitable drug to develop a generic version of.
Loved the idea and the list? Thank us later in the comments section. Now onto the list.
The article has a list of drug patents expiring in 2023. You can get the drug patents expiration list from 2026 to 2030 in a PDF by filling out the form below.
[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][mk_fancy_title color=”#2878bf” size=”32″ line_height=”80″ font_weight=”bolder” txt_transform=”uppercase” margin_bottom=”0″ font_family=”none”]Drug Patents Expiring in 2023[/mk_fancy_title][mk_divider margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Entresto
Sacubitril; Valsartan
[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$1.7 Billion (2018)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US8404744 | July 14, 2023 |
| US8796331 | July 14, 2023 |
| US7468390 | November 27, 2023 |
| US8101659 | January 15, 2025 |
[/mk_table][vc_column_text css=”.vc_custom_1614603625304{margin-bottom: 0px !important;}”]Dosage: Tablet; Oral
Company: Novartis Pharmaceuticals Corporation
Ingredients: Sacubitril; Valsartan
Treatment: Chronic Heart Failure[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Spinraza
Nusinersen Sodiumz[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$1.724 Billion (2018)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7101993 | September 05, 2023 |
| US8110560 | December 05, 2025 |
| US7838657 | July 11, 2027 |
| US8361977 | May 27, 2030 |
[/mk_table][vc_column_text css=”.vc_custom_1614604342431{margin-bottom: 0px !important;}”]Dosage: Solution; Intrathecal
Company: Biogen Idec Inc
Ingredients: Nusinersen Sodium
Treatment: Spinal Muscular Atrophy[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Tegsedi
Inotersen Sodium[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$2.2 Million (Q4, 2018)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7015315 | March 21, 2023 |
| US7101993 | September 05, 2023 |
[/mk_table][vc_column_text css=”.vc_custom_1614604482327{margin-bottom: 0px !important;}”]Dosage: Solution; Subcutaneous
Company: Akcea Therapeutics Inc
Ingredients: Inotersen Sodium
Treatment: Polyneuropathy[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Dalvance
Dalbavancin Hydrochloride[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$81.9 Million (2019)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US6900175 | December 25, 2023 |
| US7115564 | November 14, 2023 |
| US7119061 | November 14, 2023 |
| US8143212 | November 14, 2023 |
[/mk_table][vc_column_text css=”.vc_custom_1614604634799{margin-bottom: 0px !important;}”]Dosage: Powder; Intravenous
Company: Allergan Sales LLC
Ingredients: Dalbavancin Hydrochloride
Treatment: To Treat Severe Skin Infections[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Zykadia
Ceritinib[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$91 Million (2016)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US9416112 | January 31, 2023 |
| US8188276 | January 31, 2023 |
| US9018204 | January 31, 2023 |
| US8835430 | January 31, 2023 |
| US7893074 | April 25, 2026 |
| US9018204 | November 20, 2027 |
| US7964592 | April 29, 2028 |
| US8039479 | June 29, 2030 |
| US9309229 | January 18, 2032 |
[/mk_table][vc_column_text css=”.vc_custom_1652967849475{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Novartis Pharmaceuticals Corp
Ingredients: Ceritinib
Treatment: Lung Cancer[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Promacta
Eltrombopag Olamine[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$330 Million (Q4, 2018)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7160870 | May 20, 2023 |
| US7547719 | January 13, 2026 |
[/mk_table][vc_column_text css=”.vc_custom_1614604803589{margin-bottom: 0px !important;}”]Dosage: Tablet; Oral
Company: Novartis Pharmaceuticals Corp
Ingredients: Eltrombopag Olamine
Treatment: Thrombocytopenia[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Rubraca
Rucaparib Camsylate[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$142 – $143 Million (2019)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US6495541 | November 22, 2023 |
| US9045487 | February 10, 2031 |
| US8754072 | February 10, 2031 |
[/mk_table][vc_column_text css=”.vc_custom_1614604883500{margin-bottom: 0px !important;}”]Dosage: Tablet; Oral
Company: Clovis Oncology Inc
Ingredients: Rucaparib Camsylate
Treatment: BRCA-Mutated Ovarian Cancer[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Mektovi
Binimetinib[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$35.1 Million (Q3, 2019)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7777050 | March 13, 2023 |
| US8178693 | March 13, 2023 |
| US8193229 | March 13, 2023 |
| US8513293 | March 13, 2023 |
| US9562016 | October 18, 2033 |
[/mk_table][vc_column_text css=”.vc_custom_1614604954057{margin-bottom: 0px !important;}”]Dosage: Tablet; Oral
Company: Array Biopharma Inc
Ingredients: Binimetinib
Treatment: Unresectable or Metastatic Melanoma with a BRAF V600 Mutation[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Zosyn
Piperacillin Sodium, Tazobactam Sodium[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$51 Million (2019)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US6900184 | April 14, 2023 |
| US7915229 | April 14, 2023 |
| US8133883 | April 14, 2023 |
[/mk_table][vc_column_text css=”.vc_custom_1614605058642{margin-bottom: 0px !important;}”]Dosage: Injectable; Injection
Company: Wyeth Pharmaceuticals LLC
Ingredients: Piperacillin Sodium; Tazobactum Sodium
Treatment: Bacterial Infections[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Boniva
Ibandronate Sodium[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$517 Million (2011)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7192938 | May 06, 2023 |
| US7410957 | May 06, 2023 |
| US7718634 | May 06, 2023 |
[/mk_table][vc_column_text css=”.vc_custom_1614605133704{margin-bottom: 0px !important;}”]Dosage: Injectable; Injection
Company: Hoffmann La Roche Inc
Ingredients: Ibandronate Sodium
Treatment: Osteoporosis[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Votrient
Pazopanib Hydrochloride[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$828 Million (2018)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7105530 | October 19, 2023 |
[/mk_table][vc_column_text css=”.vc_custom_1614605211452{margin-bottom: 0px !important;}”]Dosage: Tablet; Oral
Company: Novartis Pharmaceuticals Corp
Ingredients: Pazopanib Hydrochloride
Treatment: Soft Tissue Sarcomas and Advanced Renal Cell Carcinoma[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Tyzeka
Telbivudine[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7858594 | September 11, 2023 |
| US7589079 | September 11, 2023 |
[/mk_table][vc_column_text css=”.vc_custom_1614605309716{margin-bottom: 0px !important;}”]Dosage: Solution; Oral
Company: Novartis Pharmaceuticals Corp
Ingredients: Telbivudine
Treatment: Chronic Hepatitis B[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Exforge
Amlodipine Besylate; Hydrochlorothiazide; Valsartan[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$1.025 Billion (2019)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US8101599 | May 16, 2023 |
| US8475839 | May 16, 2023 |
[/mk_table][vc_column_text css=”.vc_custom_1614605447983{margin-bottom: 0px !important;}”]Dosage: Tablet; Oral
Company: Novartis Pharmaceuticals Corp
Ingredients: Amlodipine Besylate; Hydrochlorothiazide; Valsartan
Treatment: High Blood Pressure (Hypertension)[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Ozurdex
Dexamethasone[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$33.7 Million (Q3, 2019)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US8034366 | January 09, 2023 |
| US8034370 | January 09, 2023 |
| US9192511 | January 09, 2023 |
| US10076526 | January 09, 2023 |
| US6899717 | November 01, 2023 |
| US8506987 | January 09, 2023 |
| US10702539 | January 09, 2023 |
[/mk_table][vc_column_text css=”.vc_custom_1614605524561{margin-bottom: 0px !important;}”]Dosage: Implant; Intravitreal
Company: Allergan Inc
Ingredients: Dexamethasone
Treatment: Macular Edema following Branch Retinal Vein Occlusion (BRVO) or Central Retinal Vein Occlusion (CRVO)[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Feraheme
Ferumoxytol[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$41.7 Million (Q4, 2019)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US6599498 | June 30, 2023 |
[/mk_table][vc_column_text css=”.vc_custom_1614605588556{margin-bottom: 0px !important;}”]Dosage: Solution; Intravenous
Company: Amag Pharmaceuticals Inc
Ingredients: Ferumoxytol
Treatment: Iron Deficiency Anemia[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Patanase
Olopatadine Hydrochloride[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7977376 | February 02, 2023 |
| US8399508 | September 17, 2022 |
[/mk_table][vc_column_text css=”.vc_custom_1614606024138{margin-bottom: 0px !important;}”]Dosage: Spray, Metered; Nasal
Company: Novartis Pharmaceuticals Corp
Ingredients: Olopatadine Hydrochloride
Treatment: Congestion, Sneezing, and Runny Nose caused by Seasonal Allergies[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Mozobil
Plerixafor[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$108.3 Million (2018)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US6987102 | July 22, 2023 |
| US7897590 | July 22, 2023 |
[/mk_table][vc_column_text css=”.vc_custom_1614605732905{margin-bottom: 0px !important;}”]Dosage: Solution; Subcutaneous
Company: Genzyme Corp
Ingredients: Plerixafor
Treatment: Non-Hodgkin’s Lymphoma or Multiple Myeloma[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][vc_accordion_tab title=”Section”][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row]
[vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Oraverse
Phentolamine Mesylate[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7229630 | June 20, 2023 |
| US7569230 | October 17, 2023 |
[/mk_table][vc_column_text css=”.vc_custom_1614606111191{margin-bottom: 0px !important;}”]Dosage: Injectable; Injection
Company: Septodont Holding SAS
Ingredients: Phentolamine Mesylate
Treatment: Used for Reversal of the Soft-Tissue Anesthesia[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Ryzolt
Tramadol Hydrochloride[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7988998 | October 27, 2023 |
[/mk_table][vc_column_text css=”.vc_custom_1614606261983{margin-bottom: 0px !important;}”]Dosage: Tablet, Extended Release; Oral
Company: Purdue Pharma Products LP
Ingredients: Tramadol Hydrochloride
Treatment: Severe Pain[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Toviaz
Fesoterodine[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$69 Million (2020)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US6858650 | January 3, 2023 |
[/mk_table][vc_column_text css=”.vc_custom_1651647251679{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Pfizer
Ingredients: FESOTERODINE FUMARATE
Treatment: Overactive Bladder Syndrome (OAB)[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Ibrance
Palbociclib
[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$1.43 Billion (2020)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US6936612 | January 16, 2023 |
| US7208489 | January 16, 2023 |
| USRE47739 | March 5, 2027 |
| US10723730 | February 8, 2034 |
[/mk_table][vc_column_text css=”.vc_custom_1652962300724{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Pfizer
Ingredients: PALBOCICLIB
Treatment: HR-positive and HER2-negative breast cancer[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Vizamyl
Flutemetamol [/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7351401 | January 24, 2023 |
| US8236282 | May 21, 2024 |
| US7270800 | September 3, 2025 |
[/mk_table][vc_column_text css=”.vc_custom_1652962443623{margin-bottom: 0px !important;}”]Dosage: Intravenous
Company: GE Healthcare
Ingredients: FLUTEMETAMOL F-18
Treatment: Used as a Diagnostic Tool for Alzheimer’s disease[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Janumet
Sitagliptin/Metformin [/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$5.2 Billion (2020)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US6699871 | January 26, 2023 |
| US7326708 | May 24, 2027 |
[/mk_table][vc_column_text css=”.vc_custom_1652962566549{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Merck & Co
Ingredients: METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE
Treatment: Type 2 Diabetes[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Lexapro
Escitalopram [/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
DKK 1.83 Billion (2021)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US6916941 | February 12, 2023 |
[/mk_table][vc_column_text css=”.vc_custom_1652963159365{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Lundbeck
Ingredients: ESCITALOPRAM OXALATE
Treatment: Major Depressive Disorder or Generalized Anxiety Disorder[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Victoza
Liraglutide [/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
DKK 15.05 Billion (2021)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US6268343 | February 22, 2023 |
| US8114833 | February 13, 2026 |
[/mk_table][vc_column_text css=”.vc_custom_1652963325153{margin-bottom: 0px !important;}”]Dosage: Subcutaneous
Company: Novo Nordisk
Ingredients: LIRAGLUTIDE RECOMBINANT
Treatment: Type 2 Diabetes, Obesity, and Chronic Weight Management[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Fosamax
Alendronic Acid [/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7964212 | March 6, 2023 |
| US7488496 | August 11, 2023 |
[/mk_table][vc_column_text css=”.vc_custom_1652963425641{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Merck & Co Inc
Ingredients: ALENDRONATE SODIUM
Treatment: Osteoporosis and Paget’s Disease of Bone[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Koselugo
Selumetinib [/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$108 Million (2021)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US8178693 | March 13, 2023 |
| US7425637 | April 11, 2024 |
| US9562017 | December 12, 2026 |
| US9156795 | December 12, 2026 |
[/mk_table][vc_column_text css=”.vc_custom_1652963564568{margin-bottom: 0px !important;}”]Dosage: Oral
Company: AstraZeneca
Ingredients: SELUMETINIB SULFATE
Treatment: Neurofibromatosis type I (NF-1)[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Akynzeo
Netupitant / Palonosetron[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US6297375 | March 17, 2023 |
| US10233154 | September 25, 2035 |
| US9951016 | September 25, 2035 |
| US10961195 | September 25, 2035 |
| US10676440 | September 25, 2035 |
[/mk_table][vc_column_text css=”.vc_custom_1652963797650{margin-bottom: 0px !important;}”]Dosage: Oral, Intravenous
Company: Helsinn Therapeutics
Ingredients: NETUPITANT; PALONOSETRON HYDROCHLORIDE
Treatment: Acute and Delayed Chemotherapy-induced Nausea and Vomiting[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Kynamro
Mipomersen [/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7015315 | March 21, 2023 |
| US7511131 | January 29, 2027 |
[/mk_table][vc_column_text css=”.vc_custom_1652964110203{margin-bottom: 0px !important;}”]Dosage: Subcutaneous Injection
Company: Genzyme Corporation
Ingredients: MIPOMERSEN SODIUM
Treatment: Homozygous Familial Hypercholesterolemia[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Incruse Ellipta
Umeclidinium bromide [/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| USRE44874 | March 23, 2023 |
| US7498440 | April 27, 2025 |
| US7439393 | May 21, 2025 |
| US7488827 | December 18, 2027 |
[/mk_table][vc_column_text css=”.vc_custom_1652964247318{margin-bottom: 0px !important;}”]Dosage: Inhalation
Company: GlaxoSmithKline
Ingredients: UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE
Treatment: Chronic Obstructive Pulmonary Disease (COPD)[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Xeljanz
Tofacitinib [/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$696 Milllion (2020)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US6965027 | March 25, 2023 |
| USRE41783 | December 8, 2025 |
[/mk_table][vc_column_text css=”.vc_custom_1652964393260{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Pfizer
Ingredients: TOFACITINIB CITRATE
Treatment: Rheumatoid Arthritis, Psoriatic Arthritis, and Ulcerative Colitis[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Vocabria
Cabotegravir [/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US8080551 | April 11, 2023 |
| US7125879 | April 21, 2025 |
[/mk_table][vc_column_text css=”.vc_custom_1652964521891{margin-bottom: 0px !important;}”]Dosage: Oral, Intramuscular
Company: ViiV Healthcare
Ingredients: CABOTEGRAVIR; RILPIVIRINE
Treatment: HIV/AIDS[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Dexilant
Dexlansoprazole[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US6664276 | July 30, 2023 |
[/mk_table][vc_column_text css=”.vc_custom_1652965324896{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Takeda
Ingredients: DEXLANSOPRAZOLE
Treatment: Gastroesophageal Reflux Disease[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Dutrebis
Lamivudine/raltegravir[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7820660 | April 25, 2023 |
[/mk_table][vc_column_text css=”.vc_custom_1652964639949{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Merck Sharp & Dohme Corp.
Ingredients: LAMIVUDINE; RALTEGRAVIR POTASSIUM
Treatment: HIV/AIDS[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row]
[vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Fotivda
Tivozanib[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$38.9 Million (2021)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US6821987 | April 26, 2023 |
| US7166722 | November 16, 2023 |
[/mk_table][vc_column_text css=”.vc_custom_1652964754554{margin-bottom: 0px !important;}”]Dosage: Oral
Company: AVEO Pharmaceuticals
Ingredients: TIVOZANIB HYDROCHLORIDE
Treatment: Relapsed or Refractory Advanced Renal Cell Carcinoma (RCC)[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Banzel
Rufinamide[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US6740669 | May 14, 2023 |
[/mk_table][vc_column_text css=”.vc_custom_1652964900165{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Eisai Inc.
Ingredients: RUFINAMIDE
Treatment: Seizures Associated with Lennox-Gastaut syndrome[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Nuzyra
Omadacycline[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$38.8 million (2020)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7553828 | June 2, 2023 |
| US7326696 | September 24, 2023 |
| US8383610 | September 23, 2030 |
[/mk_table][vc_column_text css=”.vc_custom_1652965092942{margin-bottom: 0px !important;}”]Dosage: Oral, Intravenous
Company: Paratek Pharmaceuticals
Ingredients: OMADACYCLINE TOSYLATE
Treatment: Community-acquired Bacterial Pneumonia and Acute Skin and skin structure infections[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Halaven
Eribulin[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US6214865 | July 20, 2023 |
[/mk_table][vc_column_text css=”.vc_custom_1652965219877{margin-bottom: 0px !important;}”]Dosage: Intravenous
Company: Eisai Inc.
Ingredients: ERIBULIN MESYLATE
Treatment: Breast Cancer and Liposarcoma[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Dexilant
Dexlansoprazole[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US6664276 | July 30, 2023 |
[/mk_table][vc_column_text css=”.vc_custom_1652965324896{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Takeda
Ingredients: DEXLANSOPRAZOLE
Treatment: Gastroesophageal Reflux Disease[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Onglyza
Saxagliptin[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$360 Million (2021)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| USRE44186 | July 31, 2023 |
[/mk_table][vc_column_text css=”.vc_custom_1652966223061{margin-bottom: 0px !important;}”]Dosage: Oral
Company: AstraZeneca
Ingredients: METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE
Treatment: Type 2 Diabetes[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Vyvanse
Lisdexamfetamine[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
271.5 Billion JPY[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7659253 | August 24, 2023 |
| US7655630 | August 24, 2023 |
| US7662787 | August 24, 2023 |
[/mk_table][vc_column_text css=”.vc_custom_1652966380706{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Shire (Takeda)
Ingredients: LISDEXAMFETAMINE DIMESYLATE
Treatment: Attention Deficit Hyperactivity Disorder (ADHD)[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Lumigan
Bimatoprost[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$149 Million (2021)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US8038988 | August 25, 2023 |
| US7851504 | June 13, 2027 |
| US8629185 | July 15, 2031 |
[/mk_table][vc_column_text css=”.vc_custom_1652966547183{margin-bottom: 0px !important;}”]Dosage: Eye Drops
Company: Allergan
Ingredients: BIMATOPROST
Treatment: High Pressure Inside the eye including Glaucoma[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Vibativ
Telavancin[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$11.7 million (2021)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US6635618 | September 11, 2023 |
| US7531623 | January 1, 2027 |
[/mk_table][vc_column_text css=”.vc_custom_1652966675551{margin-bottom: 0px !important;}”]Dosage: Intravenous
Company: Theravance Biopharma
Ingredients: TELAVANCIN HYDROCHLORIDE
Treatment: MRSA or other Gram-positive infections[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Lupron
Leuprorelin[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$783 Million (2021)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US8470359 | October 15, 2023 |
[/mk_table][vc_column_text css=”.vc_custom_1652966812260{margin-bottom: 0px !important;}”]Dosage: Subcutaneous, Intramuscular
Company: AbbVie Inc
Ingredients: LEUPROLIDE ACETATE
Treatment: Prostate Cancer, Breast Cancer, Endometriosis, Uterine Fibroids[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Feraheme
Ferric Carboxymaltose[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$167.9 million (2020)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US11123321 | October 20, 2023 |
| US9376505 | October 20, 2023 |
| US7612109 | February 5, 2024 |
[/mk_table][vc_column_text css=”.vc_custom_1652966934937{margin-bottom: 0px !important;}”]Dosage: Intravenous
Company: AMAG Pharmaceuticals
Ingredients: FERRIC CARBOXYMALTOSE
Treatment: Iron-deficiency Anemia[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Ozanex
Ozenoxacin[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US6335447 | November 9, 2023 |
[/mk_table][vc_column_text css=”.vc_custom_1652967040794{margin-bottom: 0px !important;}”]Dosage: Topical
Company: Cipher Pharmaceuticals
Ingredients: OZENOXACIN
Treatment: Impetigo[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Stiolto® Respimat
Tiotropium/olodaterol[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7491719 | November 10, 2023 |
| US7056916 | December 7, 2023 |
| US7220742 | May 12, 2025 |
| US7727984 | January 19, 2027 |
[/mk_table][vc_column_text css=”.vc_custom_1652967172422{margin-bottom: 0px !important;}”]Dosage: Inhalation
Company: Boehringer Ingelheim Pharmaceuticals
Ingredients: OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE
Treatment: Asthma [/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Otezla
Apremilast[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$2.2 billion (2020)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7893101 | December 9, 2023 |
| US7427638 | February 16, 2028 |
[/mk_table][vc_column_text css=”.vc_custom_1652967288077{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Amgen Inc
Ingredients: APREMILAST
Treatment: Psoriasis and Psoriatic Arthritis[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Rapivab
Peramivir[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$13.9 million (2020)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US6562861 | December 16, 2023 |
[/mk_table][vc_column_text css=”.vc_custom_1652967394666{margin-bottom: 0px !important;}”]Dosage: Intravenous
Company: BioCryst Pharmaceuticals
Ingredients: PERAMIVIR
Treatment: Influenza[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]VYNDAQEL
Tafamidis/Meglumine[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$429 Million (2020)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US8168663 | December 19, 2023 |
| US7214695 | April 27, 2024 |
| US9770441 | August 31, 2035 |
[/mk_table][vc_column_text css=”.vc_custom_1652967514290{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Pfizer
Ingredients: TAFAMIDIS MEGLUMINE
Treatment: Transthyretin Amyloidosis[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Coreg
Carvedilol[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7268156 | December 27, 2023 |
[/mk_table][vc_column_text css=”.vc_custom_1652967630588{margin-bottom: 0px !important;}”]Dosage: Oral
Company: GlaxoSmithKline
Ingredients: CARVEDILOL PHOSPHATE
Treatment: High Blood Pressure, Congestive Heart Failure (CHF), and Left Ventricular Dysfunction [/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_column_text css=”.vc_custom_1615816365701{margin-bottom: 0px !important;}”]Conclusion
As a drug patent expires it expands the gateway for a number of competitors to enter the market. Tracking these patent expirations beforehand can not only help evaluate business opportunities but also help in refining market entry strategies. But there still lies legal as well as technology threats and hurdles that a generic company will face depending on the drug they choose for the generic version.
With proper research and threat analysis, developing a generic version wouldn’t be as terrifying. How to go about it? Well, let’s start with getting in touch by filling the form below and we’ll get back to you in no time.
Authored by: Divya Goyal, Team Lead, Life Science Team, and Madan Ekhande, Research Analyst, Life Science Team[/vc_column_text][/vc_column][/vc_row]
